Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.

@article{Wolf1997LongtermSA,
  title={Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.},
  author={Max M Wolf and Jane Matthews and Janey Malka Stone and Ian A. Cooper and Traesha Robertson and Richard M. Fox},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1997},
  volume={8 Suppl 1},
  pages={71-5}
}
BACKGROUND The initial publication of the results of the Australian and New Zealand Lymphoma Group (ANZLG) randomized controlled trial comparing MACOP-B and CHOP in patients with intermediate-grade non-Hodgkin's lymphoma (NHL) showed equivalent complete response rates, time to treatment failure, and survival. Here we report the long-term follow-up of the 236 patients entered on that study to determine if there were any long-term advantages or disadvantages associated with MACOP-B. PATIENTS… CONTINUE READING